Form 8-K - Current report:
SEC Accession No. 0001851734-22-000549
Filing Date
2022-09-08
Accepted
2022-09-08 08:07:22
Documents
14
Period of Report
2022-09-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20220907_8k.htm   iXBRL 8-K 28329
2 EXHIBIT 99.1 ex_421373.htm EX-99.1 12811
  Complete submission text file 0001851734-22-000549.txt   179298

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20220908.xsd EX-101.SCH 3601
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20220908_def.xml EX-101.DEF 11532
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20220908_lab.xml EX-101.LAB 15414
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20220908_pre.xml EX-101.PRE 11688
8 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20220907_8k_htm.xml XML 2594
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

EIN.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 221232582
SIC: 2834 Pharmaceutical Preparations